Scholar Rock’s Post

Excited to share my first review article titled ‘Polymer-drug conjugates as nano-sized multi-targeting systems for the treatment of Alzheimer’s disease’, in the new journal, RSC Pharmaceutics. Please read and share. Dr Colin Thompson, Gemma Barron, Paul Kong Thoo Lin #alzheimersresearch #drugdelivery #rscpharmaceutics

🚀 Breaking New Ground in Diabetes Treatment! 🚀 As a pharmacist, I’m excited to share this short video showcasing the latest advancements in diabetes care. From cell therapy and immunotherapy to artificial pancreas systems and innovative drug treatments, the future is brighter than ever for those living with diabetes. Join me in exploring how cutting-edge research is paving the way towards a potential cure, improving lives, and offering hope to millions around the world. 🌟 🔬👩⚕️ Watch the video to learn more about these groundbreaking developments! #DiabetesAwareness #Pharmacy #HealthcareInnovation #FutureOfMedicine #DiabetesCare #Pharmacist #MedicalResearch #PatientCare

How to measure disease progression in preclinical research models of kidney disease? General pharmacokinetic studies allow the assessment of biodistribution of the compounds of interest, given that kidney-specific compound administration is crucial to prevent systemic toxicity associated with long-term therapy. Kidney volume is typically assessed using ultrasound. Blood creatinine and urea measurements provide more general kidney function parameters. In addition to kidney volume and function, kidney cysts and other associated pathological lesions can be assessed by routine H&E stains. Read the full blog post here: https://lnkd.in/eT_d48-t #ADPKD #KidneyDisease #PolycysticKidneyDisease #RareDiseaseCRO #NephrologyCRO

Observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence (NICE) would view Vertex’s CRISPR-based therapy for sickle cell disease. They have their answer. NICE announced last week that it is not yet recommending Casgevy, saying in draft guidance that it wants to better understand how long the benefits of the medicine will last and whether people are in fact effectively cured or not. U.K. regulators approved the the pricey, one-time therapy last year, granting it the world’s first authorization for any CRISPR-based medicine. NICE will need to recommend the therapy for it to be offered in the National Health Service. https://trib.al/259BEmO #biotech #biotechnology #medicine #genetherapy #CRISPR #sicklecell #sicklecelldisease #Casgevy #drugdevelopment

Exciting advancements in Alzheimer's treatment are on the horizon, but recent developments reveal some regulatory hurdles. The FDA's decision not to extend fast-track status to Eisai and Biogen's subcutaneous (SC) Leqembi formulation means a separate submission is needed, delaying expected filings. Despite setbacks, SC dosing promises convenience, potentially expanding access. A recent FirstWord poll shows promising perceptions among neurologists, with 62% viewing SC Leqembi as superior. Eisai aims to address FDA requests promptly, anticipating decisions within 60 days. Stay tuned for updates on this critical development in Alzheimer's care. #AlzheimersResearch #FDARegulation #MedicalInnovation #HealthcareAdvancements #NeurologyTreatment https://lnkd.in/gqi3D87b

Exciting developments in MS treatments as the EU has approved Genentech's new twice-yearly injection for multiple sclerosis patients, promising greater convenience and an element of freedom! 💉 This revolutionary anti-CD20 therapy, OCREVUS® (ocrelizumab), offers the same dosing schedule as the existing intravenous (IV) option but comes in a 10-minute injection. No more IVs needed—huge for patient quality of life! ✅ Clinical trials of OCREVUS have shown a relapse suppression rate of over 97% in a year. Authorisation of this treatment for the central nervous system autoimmune condition in the EU is based on data from the Phase III OCARINA II trial. That's remarkable progress for those battling relapsing and primary progressive MS 🙏 #Genentech #Roche #MultipleSclerosis #MS #AutoImmune #Innovation #Healthcare #Biotechnology #ClinicalTrialSuccess #ClinicalResearch #EUApproved #LifeScience #ElixirAssociates #StaffingPartner

In this seminar by the Institute of Neuro-Immune Medicine Research, Dr. Benedict Albensi, Professor and Chair of the Department of Pharmaceutical Sciences, presents research on mitochondrial function and their role in Alzheimer’s disease https://lnkd.in/d4gnZU5i

..here we describe the future #development of #therapeutics with nuanced and tailored #efficacy profiles. I hope our work helps to treat #diseases in a more #personalized and effective manner!

BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson's Disease and Movement Disorders. New preclinical data characterizing NE3107 mechanism of action featured in oral presentation Phamacokinetic data from Phase 2a study supports potential co-administration of NE3107 with carbidopa/levodopa Separate analysis of Phase 2a study data shows evidence of motor effects of NE3107 independent of levo-dopa/ carbidopa, supporting further investigation of NE3107 as first line therapy in Parkinson’s Disease CARSON CITY, Nev., Aug. 28, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: B http://ow.ly/Gz1x104Srzp #BIVI #Alzheimers #Parkinsons

BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson's Disease and Movement Disorders. New preclinical data characterizing NE3107 mechanism of action featured in oral presentation Phamacokinetic data from Phase 2a study supports potential co-administration of NE3107 with carbidopa/levodopa Separate analysis of Phase 2a study data shows evidence of motor effects of NE3107 independent of levo-dopa/ carbidopa, supporting further investigation of NE3107 as first line therapy in Parkinson’s Disease CARSON CITY, Nev., Aug. 28, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: B http://ow.ly/Gz1x104Srzp #BIVI #Alzheimers #Parkinsons